Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
As biosimilar uptake remains modest, rebate amounts trend upward for medical benefit drugs, according to latest MagellanRx drug trend report.
Biopharma industry's arguments on rebate pass-through to patients appear to carry the day at Senate HELP Committee hearing.
Oncologists charge at least 50% more for Lupron and Aranesp than do urologists or nephrologists, researchers with Johns Hopkins and Memorial Sloan Kettering found.
Panel recommends National Academies of Sciences evaluate value frameworks like ICER, identify limitations and strengths and, if necessary, develop a new approach.
Merger could restore number of covered lives PBM will lose once its contract with Anthem expires, but there is also risk of alienating current health plan clients who don't want to contract with a competitor.